Toumai

MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery. A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.

Toumai is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.

Toumai is made by MicroPort MedBot, based in Shanghai, China, founded in 2015.

Toumai is at research stage and is not yet available for sale.

Toumai has 2 regulatory records on the DEPLOY registry: NMPA registration, granted; FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Toumai include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Toumai and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Toumai has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Toumai ranks in roughly the top 20% of surgical models tracked by the registry.

Toumai is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.

No verified deployments of Toumai are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

Toumai has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Toumai and da Vinci achieve comparable safety profiles, surgical outcomes, and postoperative results, according to peer-reviewed studies. The da Vinci system has shorter docking and console times. Toumai's key advantage is remote surgery capability, including the world's first registered clinical trial for a tele-surgical robot across cross-regional, long-distance, multi-center operations. da Vinci remains the market leader with a larger installed base.